Clinical trials: Covid-19 Infection
Hearing Loss, Chronic Pain
Facemasks and Chronic Pain Patients With Hearing Loss
Facemasks may impede communication. Impaired communication may worsen healthcare outcomes. This study explores the problem of hearing impairment in chronic pain patients, and the impact of facemasks on healthcare outcomes in…
- Trial name
- NCT06072235
- Testing
- Verbal communication
- Where
- Canada
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Salem Anaesthesia Pain Clinic
Covid19
Community Network-driven COVID-19 Testing and Vaccination of Vulnerable Populations in the Central US
This C3 project, Community network-driven COVID-19 testing of vulnerable populations in the Central US, will implement and evaluate a COVID-19 testing and vaccination approach that combines an evidence-based Social Network…
- Trial name
- C3 (NCT04743908)
- Testing
- Social Network Strategy + COVID-19 messaging
- Where
- United States
- Volunteers
- 1,328 people, healthy volunteers welcome
- Sponsor
- University of Chicago
COVID-19 Pandemic, Eating Habit
The Effect of the COVID-19 Epidemic Process on the Nutritional Habits and Body Weights of Adults
During the COVID-19 epidemic, the time spent by adults on the stomach has increased. Therefore, the likelihood of adverse changes in lifestyles has increased.
- Conditions
- COVID-19 Pandemic, Eating Habit, Weight Gain
- Trial name
- NCT05115084
- Testing
- no intervention
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Istanbul Medeniyet University
Severe Acute Respiratory Syndrome
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
OSCAR (Otilimab in Severe COVID-19 Related Disease) is a multi-center, double-blind, randomized, placebo-controlled trial to assess the efficacy and safety of otilimab for the treatment of severe pulmonary COVID-19 related…
- Trial name
- OSCAR (NCT04376684)
- Testing
- Otilimab, Standard of care
- Where
- 120 sites in United States, Argentina and 17 more
- Volunteers
- 1,156 people
- Sponsor
- GlaxoSmithKline
Sars-CoV2, Infection Viral
HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers
Background: Aim: To demonstrate the efficacy of low-dose hydroxychloroquine as primary prevention in healthcare workers Design, participants and interventions: Prospective, randomized, parallel group, double-blinded, placebo…
- Conditions
- Sars-CoV2, Infection Viral, Healthcare Worker, Prophylaxis
- Trial name
- NCT04336748
- Testing
- Hydroxychloroquine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medical University of Vienna
ARDS, Covid19
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome…
- Conditions
- ARDS, Covid19, Influenza, Human
- Trial name
- AVM0703 (NCT04366115)
- Testing
- AVM0703
- Volunteers
- 16 people
- Sponsor
- AVM Biotechnology Inc
COVID-19, Myocardial Injury
Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19
COVID-19 outbreak is often lethal. Mortality has been associated with several cardio-vascular risk factors such as diabetes, obesity, hypertension and tobacco use.
- Conditions
- COVID-19, Myocardial Injury, Myocarditis
- Trial name
- JOCOVID (NCT04320017)
- Testing
- Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
COVID-19
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial
The present study is a randomized clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical Education Center in Tehran.
- Trial name
- COVIFERON (NCT04343768)
- Testing
- Hydroxychloroquine, Lopinavir / Ritonavir, Interferon Beta-1A
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Covid-19
Oral Curcumin, Quercetin and Vitamin D3 Supplements for Mild to Moderate Symptoms of COVID-19
The present study is aimed to investigate the treatment benefits of a combination of dietary supplements quercetin, curcumin and vitamin D3 as add-on therapy to the routine care for early mild symptoms of COVID-19 infection in…
- Trial name
- NCT04603690
- Testing
- Complementary therapy, Standard of care
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- Liaquat University of Medical & Health Sciences
Long COVID-19
Long COVID-19 Intervention (COVIDL/MIQoL)
The goal of this clinical trial is to assess the effectiveness of a multicomponent intervention in individuals with Long COVID. The main questions it aims to answer are: Does the intervention increase quality of life, mental…
- Trial name
- COVIDL/MIQoL (NCT06492590)
- Testing
- Multicomponent intervention
- Where
- Spain
- Volunteers
- 74 people
- Sponsor
- Consorci Sanitari de Terrassa
Coronavirus Infection
Early Intervention in COVID-19: Favipiravir Verses Standard Care
Currently we do not know how best to treat patients infected with COVID-19. This study is looking at whether randomising participants to either favipiravir or to usual care, can help patients with suspected or proven COVID-19…
- Trial name
- PIONEER (NCT04373733)
- Testing
- Favipiravir, Standard of care management
- Where
- 6 sites in Brazil, Mexico and 1 more
- Volunteers
- 502 people
- Sponsor
- Chelsea and Westminster NHS Foundation Trust
SARS-CoV-2, Influenza
A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old
The primary goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1073 compared to co-administered mRNA-1010 and mRNA-1273 vaccines and to the individual vaccines alone in healthy participants.
- Trial name
- NCT05375838
- Testing
- mRNA-1073, mRNA-1010, mRNA-1273
- Where
- 14 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19 by SARS-CoV-2 Infection
Role of Inflammasomes in COVID-19 Disease
As of March 25, 2020, 414,179 cases and 18,440 deaths secondary to Coronavirus 2019 disease (COVID-19) have been reported worldwide.
- Trial name
- CoVInnate (NCT04385017)
- Testing
- COVID-19 patients
- Where
- 2 sites in France
- Volunteers
- 99 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Covid19
Outpatient Use of Ivermectin in COVID-19
Covid 19, a novel coronavirus, causes infection that, while mild to moderate in many people, can lead to severe disease in a significant portion.
- Trial name
- NCT04530474
- Testing
- Ivermectin Pill
- Where
- United States
- Sponsor
- Temple University
Hemophilia Arthropathy
COVID-19 Quarantine on Musculoskeletal Status in Hemophilia
Background. The recurrence of hemarthrosis in patients with congenital coagulopathies favors the development of a progressive, degenerative and intra-articular lesion (hemophilic arthropathy) that mainly affects the knees, ankles…
- Trial name
- HemoCov (NCT04491318)
- Testing
- Observational
- Where
- Spain
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Investigación en Hemofilia y Fisioterapia
Respiratory Failure
Gas Exchange Derangement Physiopathology in Critically Ill Patients With COVID-19
The study was designed to understand the pathophysiology of gas exchange derangement in critically ill patients with COVID-19. Specifically we will evaluate the effect of 3 different levels of positive end-expiratory pressure…
- Trial name
- NCT05132933
- Testing
- PEEP trial - Electrical Impedance Tomography
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Policlinico Hospital
Dysphagia, Covid19
Dysphagia Management During COVID-19 Pandemic
The current study is aimed to determine the procedures applied in the dysphagia clinics during the COVID-19 pandemic period. A questionnaire consisting of 30 questions will be implemented.
- Trial name
- NCT04509752
- Testing
- Survey
- Where
- Turkey (Türkiye)
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
COVID-19
Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19
This study is a randomized, double-blinded, and placebo-controlled phase Ia/IIa clinical trial of the Inactivated SARS-CoV-2 Vaccine to evaluate the safety and immunogenicity of the vaccine in healthy people aged 18~59 Years.
- Trial name
- NCT04412538
- Testing
- Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule, Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule, Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
- Where
- China
- Volunteers
- 942 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
Inflammatory Bowel Diseases
Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease
The aim of this study is to determine the impact of systemic immunosuppression on sustained antibody COVID-19 concentrations in patients with IBD who received a COVID-19 vaccine.
- Trial name
- NCT05014555
- Testing
- COVID-19 Vaccine
- Where
- 4 sites in United States
- Volunteers
- 400 people
- Sponsor
- GI Alliance
COVID-19 Pandemic, COVID-19 Vaccines
UNAIR Inactivated COVID-19 Vaccine as Homologue Booster (Immunobridging Study)
The goal of this open-label clinical trial is to evaluate the safety and immunogenicity of INAVAC (Vaksin Merah Putih - UNAIR SARS-CoV-2 (Vero Cell Inactivated)) Vaccine as Homologue Booster in Adult Subjects in Indonesia.
- Conditions
- COVID-19 Pandemic, COVID-19 Vaccines, COVID-19 Virus Disease
- Trial name
- NCT06259578
- Testing
- INAVAC (Vaksin Merah Putih - UA- SARS CoV-2 (Vero Cell Inactivated) 5 μg
- Where
- Indonesia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital